


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app42.us.archive.org';v.server_ms=252;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180713052426im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180713052426im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180713052426im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180713052426im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180713052426/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180713052426im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180713052426cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180713052426js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180713052426if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713052426/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180713052426if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713052426/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180713052426/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180713052426/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180713052426/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180713052426/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180713052426/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180713052426/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180713052426/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180713052426/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180713052426/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180713052426/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180713052426/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180713052426/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180713052426/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180713052426/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180713052426/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180713052426/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180713052426/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180713052426/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180713052426/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180713052426/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180713052426/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180713052426/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180713052426/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180713052426/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010488</li>
            <li>2014 Jul
            </li>            
                                </ul>
        <div>
                <h1>The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180713052426/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20Association%20of%20Neurological%20Surgeons&amp;fLockTerm=American%2BAssociation%2Bof%2BNeurological%2BSurgeons">American Association of Neurological Surgeons</a></li>
                        <li>   
                                <a id="399" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
        <li><a href="/web/20180713052426/https://www.guideline.gov/search?f_Guideline_Developer_String=Congress%20of%20Neurological%20Surgeons&amp;fLockTerm=Congress%2Bof%2BNeurological%2BSurgeons">Congress of Neurological Surgeons</a></li>
                        <li>   
                                <a id="1873" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC, AANS/CNS Joint Guidelines Committee. The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul;118(3):557-99. [157 references] <a href="https://web.archive.org/web/20180713052426/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24740195" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713052426im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180713052426/https://www.guideline.gov/Home/Disclaimer?id=48377&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252flink.springer.com%252farticle%252f10.1007%252fs11060-013-1339-4%252ffulltext.html">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713052426im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180713052426/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
                        <li><a href="/web/20180713052426/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&amp;fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>                      
                        <li><a href="/web/20180713052426/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&amp;fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>                      
                        <li><a href="/web/20180713052426/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180713052426/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180713052426/https://www.guideline.gov/search?f_ICD9CM_CUI=C0153633&amp;fLockTerm=Malignant+neoplasm+of+brain%2c+unspecified">Malignant neoplasm of brain, unspecified</a>
 (191.9), <a href="/web/20180713052426/https://www.guideline.gov/search?f_ICD9CM_CUI=C0006118&amp;fLockTerm=Neoplasm+of+unspecified+nature+of+brain">Neoplasm of unspecified nature of brain</a>
 (239.6)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180713052426/https://www.guideline.gov/search?f_MSH_CUI=C0596087&amp;fLockTerm=Angiogenesis+Inhibitors">Angiogenesis Inhibitors</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MSH_CUI=C2985546&amp;fLockTerm=Antibodies%2c+Monoclonal%2c+Humanized">Antibodies, Monoclonal, Humanized</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MSH_CUI=C0796392&amp;fLockTerm=Bevacizumab">Bevacizumab</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MSH_CUI=C0006118&amp;fLockTerm=Brain+Neoplasms">Brain Neoplasms</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MSH_CUI=C0008976&amp;fLockTerm=Clinical+Trials+as+Topic">Clinical Trials as Topic</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MSH_CUI=C0242656&amp;fLockTerm=Disease+Progression">Disease Progression</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MSH_CUI=C0017636&amp;fLockTerm=Glioblastoma">Glioblastoma</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180713052426/https://www.guideline.gov/search?f_MTH_CUI=C0596087&amp;fLockTerm=Angiogenesis+Inhibitors">Angiogenesis Inhibitors</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MTH_CUI=C0796392&amp;fLockTerm=bevacizumab">bevacizumab</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MTH_CUI=C0006118&amp;fLockTerm=Brain+Neoplasms">Brain Neoplasms</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MTH_CUI=C0008976&amp;fLockTerm=Clinical+Trials">Clinical Trials</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MTH_CUI=C0242656&amp;fLockTerm=Disease+Progression">Disease Progression</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MTH_CUI=C0017636&amp;fLockTerm=Glioblastoma">Glioblastoma</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_MTH_CUI=C0153633&amp;fLockTerm=Malignant+neoplasm+of+brain">Malignant neoplasm of brain</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180713052426/https://www.guideline.gov/search?f_PDQ_CUI=C0796392&amp;fLockTerm=bevacizumab">bevacizumab</a>
, <a href="/web/20180713052426/https://www.guideline.gov/search?f_PDQ_CUI=C0006118&amp;fLockTerm=brain+tumor">brain tumor</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0596087&amp;fLockTerm=Angiogenesis+inhibitor">Angiogenesis inhibitor</a>
 (409407003), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0596087&amp;fLockTerm=Angiogenesis+inhibitor">Angiogenesis inhibitor</a>
 (409408008), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0796392&amp;fLockTerm=Bevacizumab">Bevacizumab</a>
 (409405006), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0796392&amp;fLockTerm=Bevacizumab">Bevacizumab</a>
 (409406007), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0008976&amp;fLockTerm=Clinical+trial">Clinical trial</a>
 (110465008), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0242656&amp;fLockTerm=Course+of+illness">Course of illness</a>
 (246453008), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0017636&amp;fLockTerm=Glioblastoma">Glioblastoma</a>
 (63634009), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0153633&amp;fLockTerm=Malignant+neoplasm+of+brain">Malignant neoplasm of brain</a>
 (428061005), <a href="/web/20180713052426/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006118&amp;fLockTerm=Neoplasm+of+brain">Neoplasm of brain</a>
 (126952004)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/downloadcontent/ngc-10488?contentType=pdf" class="pdf">.PDF 78.6 kb</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/downloadcontent/ngc-10488?contentType=word" class="word">Word Document 280.5 kb</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/downloadcontent/ngc-10488?contentType=xml" class="xml">.XML 30.5 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180713052426/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713052426/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713052426/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180713052426/mailto:/?Subject=AHRQ: The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline.&amp;body=https://www.guideline.gov/summaries/summary/48377/the-role-of-targeted-therapies-in-the-management-of-progressive-glioblastoma-a-systematic-review-and-evidencebased-clinical-practice-guideline" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2014 Jul 01. [cited 2018 Jul 13]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/citedownload/48377?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/citedownload/48377?format=enw">EndNote</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/citedownload/48377?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/citedownload/48377?format=txt">Medlars</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/citedownload/48377?format=ris">ProCite</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/citedownload/48377">RefWorks</a></li>
                            <li><a href="/web/20180713052426/https://www.guideline.gov/summaries/citedownload/48377?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="48377" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>The rating schemes used for the strength of the evidence (<strong>Class I-III</strong>) and the levels of recommendations (<strong>Level 1-3</strong>) are defined at the end of the "Major Recommendations" field.</p>
<p><span style="text-decoration: underline;"><strong>Recommendation</strong></span></p>
<p><strong>Level III</strong></p>
<p>Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months.</p>
<p>Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.</p>
<p><span style="text-decoration: underline;"><strong>Definition</strong></span>:</p>
<p><strong>Evidence Classification for Therapeutic Studies</strong></p>
<p><strong>Class I</strong>: Evidence provided by one or more well-designed randomized controlled clinical trials, including overview (meta-analyses) of such trials</p>
<p><strong>Class II</strong>: Evidence provided by well-designed observational studies with concurrent controls (e.g., case control and cohort studies)</p>
<p><strong>Class III</strong>: Evidence provided by expert opinion, case series, case reports and studies with historical controls</p>
<p><strong>Evidence Classification for Diagnostic Studies</strong></p>
<p><strong>Class I</strong>: Evidence provided by one or more well-designed clinical studies of a diverse population using a "gold standard" reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and where applicable, likelihood ratios</p>
<p><strong>Class II</strong>: Evidence provided by one or more clinical studies of a restricted population using a "gold standard" reference test in a blinded evaluation of diagnostic accuracy and enabling assessment of sensitivity, specificity, positive and negative predictive values, and where applicable, likelihood ratios</p>
<p><strong>Class III</strong>: Evidence provided by expert opinion, studies that do not meet the criteria for the delineation of sensitivity, specificity, positive and negative predictive values, and where applicable, likelihood ratios</p>
<p><strong>Levels of Recommendation</strong></p>
<p><strong>Level 1</strong>: Generally accepted principles for patient management, which reflect a high degree of clinical certainty (usually this requires Class I evidence which directly addresses the clinical questions or overwhelming Class II evidence when circumstances preclude randomized clinical trials)</p>
<p><strong>Level 2</strong>: Recommendations for patient management which reflect clinical certainty (usually this requires Class II evidence or a strong consensus of Class III evidence)</p>
<p><strong>Level 3</strong>: Other strategies for patient management for which the clinical utility is uncertain (inconclusive or conflicting evidence or opinion)</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Progressive glioblastoma</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Management</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Neurology</p>
                    <p>Oncology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Hospitals</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>To provide a cataloging, review, and systematic evaluation of progressive glioblastoma treatments to allow the practicing physician to determine their role in patient management </li>
    <li>To provide the latest up-to-date evidence-based recommendations for the management of patients with progressive glioblastoma centering on questions related to commonly encountered clinical scenarios </li>
</ul></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Adult patients with progressive glioblastoma</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;" start="1">
    <li>Bevacizumab </li>
    <li>Enrollment in properly designed clinical investigations </li>
</ol>
<p class="Note"><strong>Note</strong>: See the original guideline document for detailed information concerning other interventions that were considered but not recommended.</p></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Improvement in average life expectancy </li>
    <li>Time of disease progression </li>
    <li>Improved disease control </li>
    <li>Quality of life </li>
    <li>Survival </li>
    <li>Mortality </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Hand-searches of Published Literature (Primary Sources)</p>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>The following electronic databases were searched from January 1990 through June 2012: MEDLINE and EMBASE. A broad search strategy using a combination of subheadings and text words was employed. In brief, a search was executed for progressive glioblastoma treatment with targeted therapies. Specifically that included progressive, recurrent, or relapsing glioma or glioblastoma and combined with targeted therapy and molecular agents and then quality of life, survival and mortality. The search strategy is documented in the companion document (see the "Availability of Companion Documents" field). Reference lists of included studies were also reviewed.</p>
<p><strong>Literature Eligibility Criteria</strong></p>
<ul style="list-style-type: disc;">
    <li>Published in English </li>
    <li>Adult patients (age &ge;18) with progressive glioblastoma were included in the study and the data on their outcomes could be separated from other histologies </li>
    <li>Fully published (i.e., not in abstract form) peer reviewed primary studies involving targeted therapy used alone or in combinations </li>
    <li>Number of study participants with progressive glioblastoma &ge;5 </li>
    <li>For studies with mixed histologic populations, baseline pretreatment and outcome information on study participants is provided for patients with progressive glioblastoma separate from other histologies </li>
    <li>For studies with consideration of more than one treatment regimen, baseline pretreatment and outcome information on study participants is provided in a manner that can be separated by treatment </li>
</ul></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>The search resulted in 232 publications being identified as having potential relevance. Importantly the search for  cytotoxic chemotherapy related publications identified a number of manuscripts also dealing with targeted therapies and resulted in additions to this group. A total of 1,673 publications were identified by the search method and underwent title and abstract screening. Of those, 299 were deemed better information regarding this guideline.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Evidence Classification for Therapeutic Studies</strong></p>
<p><strong>Class I</strong>: Evidence provided by one or more well-designed randomized controlled clinical trials, including overview (meta-analyses) of such trials</p>
<p><strong>Class II</strong>: Evidence provided by well-designed observational studies with concurrent controls (e.g., case control and cohort studies)</p>
<p><strong>Class III</strong>: Evidence provided by expert opinion, case series, case reports and studies with historical controls</p>
<p><strong>Evidence Classification for Diagnostic Studies</strong></p>
<p><strong>Class I</strong>: Evidence provided by one or more well-designed clinical studies of a diverse population using a "gold standard" reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and where applicable, likelihood ratios</p>
<p><strong>Class II</strong>: Evidence provided by one or more clinical studies of a restricted population using a "gold standard" reference test in a blinded evaluation of diagnostic accuracy and enabling assessment of sensitivity, specificity, positive and negative predictive values, and where applicable, likelihood ratios</p>
<p><strong>Class III</strong>: Evidence provided by expert opinion, studies that do not meet the criteria for the delineation of sensitivity, specificity, positive and negative predictive values, and where applicable, likelihood ratios</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Studies which met the eligibility criteria had their data extracted by one reviewer and the extracted information was checked by a second reviewer. Evidence and summary tables, reporting the extracted study information and evidence classification, were generated for all of the included studies for each of the questions. The literature in the evidence tables was expanded upon in the scientific foundation of each section so as to emphasize important points supporting its classification and contribution to recommendations.</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>Writing groups were created from the entire clinical guideline panel based on expertise to address each of the disciplines and areas of therapy chosen to be part of this set of clinical guidelines. Each group was involved with literature selection, creation and editing of the evidence/summary tables for their specific discipline. Using this information, the writing groups then drafted the clinical practice guideline for their respective discipline. The draft guidelines were then circulated to the entire clinical guideline panel for feedback, discussion, and ultimately approval.</p>
<p>Both the evidence classification and the strength of the recommendations were graded according to the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) (see the "Rating Scheme for the Strength of the Evidence" and "Rating Scheme for the Strength of the Recommendations" fields). The class of evidence assigned to each study was based on study design (i.e., class I, II, or III). The strength of the recommendations made (i.e., level 1, 2, or 3) was directly linked to the evidence classification and took into account aspects of study quality and whether or not the plan was accomplished, not just study design. Specifically, the level of a recommendation made could be decreased, based on consensus input, if there were methodological concerns regarding the studies that provided evidence for that particular recommendation.</p>
<p>See Figure 1 in the methodology document (see the "Availability of Companion Documents" field) for an outline of the key steps in the process of developing these clinical practice guidelines.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Levels of Recommendation</strong></p>
<p><strong>Level 1</strong>: Generally accepted principles for patient management, which reflect a high degree of clinical certainty (usually this requires Class I evidence which directly addresses the clinical questions or overwhelming Class II evidence when circumstances preclude randomized clinical trials)</p>
<p><strong>Level 2</strong>: Recommendations for patient management which reflect clinical certainty (usually this requires Class II evidence or a strong consensus of Class III evidence)</p>
<p><strong>Level 3</strong>: Other strategies for patient management for which the clinical utility is uncertain (inconclusive or conflicting evidence or opinion)</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>The completed evidence-based clinical practice guidelines on the diagnosis and management of progressive glioblastoma were presented to the Joint Guidelines Committee (JGC) of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) for approval. The reviewers for the JGC were vetted by the Journal of Neuro-Oncology for suitability and expertise to serve as reviewers for the purposes of publication in that journal also. As part of their evaluation process, the JGC reviewers could provide input on the content of the clinical practice guidelines.</p>
<p>Development of this set of evidence-based clinical practice guidelines was editorially independent from the funding agencies. The funding agencies (CNS Executive Committee, and AANS/CNS Joint Tumor Section Executive Committee) review of these guideline papers, following JGC assessment and recommendations for endorsement but prior to submission for publication, was limited to whether or not to endorse or reject this body of work.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate treatment of patients with progressive glioblastoma with bevacizumab to improve survival outcomes</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>The use of bevacizumab alone is not without toxicities as the authors of one study report the most common grade 3 or greater toxicities for the use of this agent alone include hypertension (8.3%) and convulsions (6.0%).</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>The information in these guidelines reflects the current state of knowledge at the time of completion. The presentations are designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient's physician(s). If medical advice or assistance is required, the services of a physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC, AANS/CNS Joint Guidelines Committee. The role of targeted therapies in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul;118(3):557-99. [157 references] <a href="https://web.archive.org/web/20180713052426/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24740195" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713052426im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2014 Jul</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>American Association of Neurological Surgeons - Medical Specialty Society</p>
                    <p>Congress of Neurological Surgeons - Professional Association</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>These guidelines were funded exclusively by the CNS and Tumor Section of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons (CNS) whom received no funding from outside commercial sources to support the development of this document unless otherwise stated in this section.</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Guideline Panel</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Authors</em>: Jeffrey J. Olson, MD, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA; Lakshmi Nayak, MD, Dana-Farber Cancer Institute, Boston, MA, Department of Neurology Brigham and Women's Cancer Center, Boston, MA; David Ryan Ormond, MD, Department of Neurological Surgery, Emory University School of Medicine, Atlanta, GA; Patrick Y. Wen, MD, Dana-Farber Cancer Institute, Boston, MA, Department of Neurology, Brigham and Women's Cancer Center, Boston, MA; Steven N. Kalkanis, MD, Department of Neurosurgery, Henry Ford Health System, Detroit, MI; Timothy Charles Ryken, MD, MS, FACS, Department of Neurosurgery, Iowa Spine and Brain Institute, Iowa City, IA</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Task Force Members report potential conflicts of interest (COI) prior to beginning work on the guideline and at the time of publication. COI disclosures are reviewed by the Task Force Chair and taken into consideration when determining writing assignments. Resolution of potential COIs included Task Force members&nbsp;being assigned to chapters that did not involve or in any way relate to the potential COIs disclosed.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available to subscribers from the <a href="/web/20180713052426/https://www.guideline.gov/Home/Disclaimer?id=48377&amp;contentType=summary&amp;redirect=http%3a%2f%2flink.springer.com%2farticle%2f10.1007%2fs11060-013-1339-4%2ffulltext.html" title="Journal of Neuro-Oncology Web site">Journal of Neuro-Oncology Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713052426im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following is available:</p>
<ul style="list-style-type: disc;">
    <li>Olson JJ, Ryken TC. Kalkanis SN. Introduction, rationale, and methodology. J Neurooncol. 2014 Jul;118(3): 429&ndash;434. Available to subscribers from the <a href="/web/20180713052426/https://www.guideline.gov/Home/Disclaimer?id=48377&amp;contentType=summary&amp;redirect=http%3a%2f%2flink.springer.com%2farticle%2f10.1007%2fs11060-013-1329-6%2ffulltext.html" title="Journal of Neuro-Oncology Web site">Journal of Neuro-Oncology Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713052426im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on September 3, 2014.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180713052426/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180713052426/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180713052426/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713052426/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713052426/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713052426/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713052426/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713052426/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180713052426/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180713052426/https://www.guideline.gov/disclaimer?id=48377&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180713052426/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180713052426/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180713052426/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180713052426/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180713052426/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180713052426/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180713052426/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180713052426/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180713052426/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180713052426/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180713052426/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180713052426/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180713052426/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180713052426/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180713052426im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180713052426/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180713052426/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180713052426js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180713052426js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 05:24:26 Jul 13, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 18:01:17 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 77.788 (3)
  esindex: 0.012
  captures_list: 104.846
  CDXLines.iter: 19.155 (3)
  PetaboxLoader3.datanode: 99.832 (4)
  exclusion.robots: 0.318
  exclusion.robots.policy: 0.3
  RedisCDXSource: 1.789
  PetaboxLoader3.resolve: 66.594
  load_resource: 106.517
-->